Abstract: A daylight illumination system for integration into a building or larger vehicle comprises a translucent facade element (800) containing a glass sheet and a light redirection element (302 or 708), and a light transport channel (801) for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building, characterised in that the light redirection element (302 or 708) is formed as a structured polymer film or sheet attached to a glass sheet of the facade element (800) and is configured for changing the direction of incident light into the about horizontal light transport channel.

Abstract: A daylight illumination system for integration into a building or larger vehicle comprises a translucent facade element (800) containing a glass sheet and a light redirection element (302 or 708), and a light transport channel (801) for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building, characterised in that the light redirection element (302 or 708) is formed as a structured polymer film or sheet attached to a glass sheet of the facade element (800) and is configured for changing the direction of incident light into the about horizontal light transport channel.

Abstract: A daylighting panel for integration into a building or larger vehicle comprises a translucent facade element (800) containing a glass sheet and a light transport channel (801) for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building equipped with a luminaire (807), characterised in that the inner walls including the rear end are covered by a reflecting layer (808).

Abstract: A daylight illumination system for integration into a building or larger vehicle comprises a translucent facade element (800) containing a glass sheet and a light redirection element (302 or 708), and a light transport channel (801) for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building, characterised in that the light redirection element (302 or 708) is formed as a structured polymer film or sheet attached to a glass sheet of the facade element (800) and is configured for changing the direction of incident light into the about horizontal light transport channel.

Abstract: Described herein is a structured reflector for a photovoltaic module, where the structured reflector provides improved light conversion and efficiency, and a photovoltaic module comprising the reflector. In a photovoltaic module, a reflector sheet is arranged below photovoltaic cells, with a microstructured surface of the reflector sheet facing towards the cells. The microstructured surface comprises three-dimensional reflectors in the form of cones, whose apexes direct towards an upper surface of the photovoltaic module and whose aperture ranges from 100° to 140°.

Abstract: A daylighting panel for integration into a building or larger vehicle comprises a translucent facade element (800) containing a glass sheet and a light transport channel (801) for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building equipped with a luminaire (807), characterised in that the inner walls including the rear end are covered by a reflecting layer (808).

Abstract: A daylight illumination system for integration into a building or larger vehicle comprises a translucent facade element (800) containing a glass sheet and a light redirection element (302 or 708), and a light transport channel (801) for guiding light about horizontally into an interior of the building, the light transport channel comprising one opening attached to the interior side of said facade element and at least one opening towards the interior of the building, characterised in that the light redirection element (302 or 708) is formed as a structured polymer film or sheet attached to a glass sheet of the facade element (800) and is configured for changing the direction of incident light into the about horizontal light transport channel.

Abstract: The present invention provides a photolatent Ti-chelate catalyst formulation, comprising (i) at least one compound of the formula (I) wherein R1 is C1-C20alkyl or C2-C20alkyl which is interrupted by one or more non-consecutive O-atoms; Y is formula (II) or optionally substituted phenyl; Y1 is formula (III) or optionally substituted phenyl; Y2 is formula (IV) or optionally substituted phenyl; Y3 is formula (V) or optionally substituted phenyl; R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 independently of each other are hydrogen, halogen, optionally substituted C1-C20alkyl, or R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 and R13 independently of each other are optionally substituted C6-C14aryl, provided that only one of R2, R3, R4 is hydrogen and only one of R5, R6, R7 is hydrogen and only one of R8, R9, R10 is hydrogen and only one of R11, R12, R13 is hydrogen; and (ii) at least one chelate ligand compound of the formula IIa, IIb or IIc, wherein Y? is formula (VI) or formula (VII); Y?1 is formula (VI

Abstract: The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and solvents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.

Abstract: The present invention primarily relates to multicomponent crystals comprising a compound of formula 1 and a second compound selected from the group consisting of menthol and vanillin. The invention is further related to pharmaceutical compositions comprising such multicomponent crystals. Furthermore, the invention relates to processes for preparing said multicomponent crystals. The invention also relates to several aspects of using said multicomponent crystals or pharmaceutical compositions to treat a disease.

Abstract: Combinations of (3?)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acid are useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.

Abstract: A titanium-oxo-chelate catalyst formulation, comprising: (i) at least one compound of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 independently of each other are for example hydrogen, halogen, C1-C20alkyl, C6-C14aryl which is unsubstituted or substituted; or R1, R2 and R3 and/or R4, R5 and R6 and/or R7, R8 and R9 and/or R10, R11 and R12 together with the C-atom to which they are attached each form a C6-C14aryl group which is unsubstituted or substituted; or R1 and R2 and/or R4 and R5 and/or R7 and R8 and/or R10 and R11 together with the C-atom to which they are attached form a 5- to 7-membered carbocyclic ring; at least one chelate ligand compound of the formula (IIa), (IIb) or (IIc), wherein R1, R2, R3, R4, R5 and R6 are defined as above for formula (I), is suitable as a photolatent catalyst formulation for polymerizing compounds, which are capable to crosslink in the presence of a Lewis acid.

Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

Abstract: A titanium-oxo-chelate catalyst formulation, comprising: (i) at least one compound of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 independently of each other are for example hydrogen, halogen, C1-C20alkyl, C6-C14aryl which is unsubstituted or substituted; or R1, R2 and R3 and/or R4, R5 and R6 and/or R7, R8 and R9 and/or R10, R11 and R12 together with the C-atom to which they are attached each form a C6-C14aryl group which is unsubstituted or substituted; or R1 and R2 and/or R4 and R5 and/or R7 and R8 and/or R10 and R11 together with the C-atom to which they are attached form a 5- to 7-membered carbocyclic ring; at least one chelate ligand compound of the formula (IIa), (IIb) or (IIc), wherein R1, R2, R3, R4, R5 and R6 are defined as above for formula (I), is suitable as photolatent catalyst formulation for polymerizing compounds, which are capable to crosslink in the presence of a Lewis acid.

Abstract: The present invention primarily relates to multi-component crystals comprising a compound of formula 1 and a second compound selected from the group consisting of co-crystal formers and solvents. The invention is further related to pharmaceutical compositions comprising such multi-component crystals. Furthermore, the invention relates to processes for preparing said multi-component crystals. The invention also relates to several aspects of using said multi-component crystals or pharmaceutical compositions to treat a disease.

Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.

Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.

Abstract: The present invention relates to a process for preparing a graphene nanoribbon, which comprises: (a) providing at least one aromatic monomer compound which is selected from at least one polycyclic aromatic monomer compound, at least one oligo phenylene aromatic monomer compound, or combinations thereof, on a solid substrate, (b) polymerization of the aromatic monomer compound so as to form at least one polymer on the surface of the solid substrate, (c) at least partially cyclodehydrogenating the one or more polymers of step (b), wherein at least step (b) is carried out at a total pressure p(total) of at least 1×10?9 mbar; and a partial oxygen pressure p(O2) and partial water pressure p(H2O) which satisfy the following relation: p(O2)×p(H20)<3×10?14 mbar2.

Abstract: Combinations of (3?)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acidare useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.

Abstract: In a process for purifying graphene nanoribbons, a composition comprising graphene nanoribbons GNR1 and at least one contaminant is brought into contact with a liquid medium that includes a dispersant. The graphene nanoribbons GNR1 are dispersed in the liquid medium so as to obtain a liquid dispersion of the graphene nanoribbons GNR1. The liquid dispersion of the graphene nanoribbons GNR1 is subjected to a separation treatment so as to at least partly remove the at least one contaminant, thereby obtaining a liquid dispersion of purified graphene nanoribbons GNR1.